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AbstrAct
Objective Using primary care data obtained from the 
UK Clinical Practice Research Datalink, this retrospective 
cohort study examined the relationships between 
medication adherence and clinical outcomes in patients 
with type 2 diabetes.
Research design and methods Data were extracted for 
patients treated between 2008 and 2016, and stratified by 
oral antihyperglycemic agent (OHA) line of therapy (mono, 
dual or triple therapy). Patients were monitored for up to 
365 days; associations between medication possession 
ratio (MPR) and outcomes at 1 year (glycated hemoglobin 
A1c (HbA1c), weight and hypoglycemia incidence) were 
assessed using linear regression modeling and descriptive 
analyses.
Results In total, 33 849 patients were included in the 
study (n=23 925 OHA monotherapy; n=8406 OHA dual 
therapy; n=1518 OHA triple therapy). One-year change in 
HbA1c was greater among adherent (−0.90 to −1.14%; 
−9.8 to −12.5 mmol/mol) compared with non-adherent 
patients (−0.49 to −0.69%; −5.4 to −7.5 mmol/mol). On 
average, adherent patients had higher hypoglycemia event 
rates than non-adherent patients (rate ratios of 1.24, 1.10 
and 2.06 for OHA mono, dual and triple therapy cohorts, 
respectively) and experienced greater weight change from 
baseline. A 10% improvement in MPR was associated 
with −0.09% (−1.0 mmol/mol), −0.09% (−1.0 mmol/mol) 
and −0.21% (−2.3 mmol/mol) changes in HbA1c for OHA 
mono, dual and triple therapy cohorts, respectively.
Conclusions For patients with type 2 diabetes, increasing 
medication adherence can bring about meaningful 
improvements in HbA1c control as the requirement for 
treatment escalation increases. Regimens associated 
with weight loss and the avoidance of hypoglycemia were 
generally associated with better medication adherence and 
improved glycemic control.
InTROduCTIOn
Optimal glycemic management is essential to 
avoid the downstream health and economic 
consequences of type 2 diabetes, both at a 
patient and population level. In addition to 
dietary and lifestyle factors, choice of medica-
tion for type 2 diabetes represents a key deter-
minant of the achievement and maintenance 
of glycemic control.
The evolution of type 2 diabetes is char-
acterized by elevations in glycated hemo-
globin A1c (HbA1c) levels over time and 
an ongoing requirement to adjust medica-
tion with respect to glucose-lowering effi-
cacy, patient preferences and side effect 
profiles. In patients newly diagnosed with 
type 2 diabetes, metformin (MET) or sulfo-
nylurea (SU) are common first-line thera-
peutic strategies.1 These therapies often elicit 
a good, initial glucose-lowering response; 
however, in patients who experience intol-
erable side effects (including gastrointes-
tinal symptoms and/or hypoglycemia) or do 
not achieve sufficient glycemic control with 
these therapies (initially or over time as the 
disease progresses), there is a requirement 
significance of this study
What is already known about this subject?
 ► The glucose-lowering efficacy of type 2 diabetes 
medications may only be realized through optimal 
patient adherence; a factor negatively impacted by 
treatment-related side effects such as weight gain 
and hypoglycemia.
What are the new findings?
 ► Using real-world data from 33 849 patients with 
type 2 diabetes in UK clinical practice, this study 
found that across oral antihyperglycemic agent 
(OHA) lines of therapy (mono, dual or triple therapy), 
regimens typically associated with weight loss and 
lower incidence of hypoglycemia were generally 
associated with better medication adherence, 
which in turn was related to improved glycemic 
control.
How might these results change the focus of 
research or clinical practice?
 ► For patients with type 2 diabetes requiring therapy 
escalation across the OHA treatment paradigm, 
data from this study have identified important 
determinants of optimal medication adherence and 
glycemic management.
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to escalate to alternative monotherapy or combination 
regimens. These may include other oral antihypergly-
cemic agents (OHA) such as thiazolidinedione (TZD), 
sodium-glucose co-transporter-2 inhibitors (SGLT-2i) 
and dipeptidyl peptidase-4 inhibitors (DPP-4i) or inject-
able regimens including glucagon-like peptide-1 (GLP-1) 
and insulin-based therapies.1 These alternative classes 
of medication are each associated with unique efficacy 
and side effect profiles which, on their own or in combi-
nation, may determine patient adherence and levels of 
glycemic control.2
The glucose-lowering potential of medication may 
only be realized through optimal medication adher-
ence. Factors recognized by patients with diabetes 
to negatively impact their adherence to medication 
include the incidence of treatment-related side effects, 
particularly weight gain and hypoglycemia.3 Research 
evaluating the impact of administering OHAs inter-
mittently, rather than as recommended,1 found that 
patients with type 2 diabetes and decreasing levels 
of medication adherence were consistently associ-
ated with a smaller HbA1c reductions compared with 
adherent patients.4 In clinical terms, the UK Prospec-
tive Diabetes Study demonstrated that each 1% (11 
mmol/mol) reduction in HbA1c reduced the risk of 
diabetes-related death by 21%, myocardial infarction 
by 14%, stroke by 12% and microvascular complications 
by 37%.5 In economic terms, Baxter and colleagues 
reported that by maintaining HbA1c levels recom-
mended by the National Institute for Health and Care 
Excellence, cost reductions could total £299 million 
over 5 years across the UK adult type 2 diabetes popu-
lation, rising to £4.5 billion over 25 years.6 In general, 
poor medication adherence in type 2 diabetes has been 
found to negatively influence time to treatment inten-
sification,7 rate of hospitalizations8 and healthcare 
expenditure9 related to diabetes-related morbidity and 
mortality.
Given that type 2 diabetes is characterized by the need 
to adjust treatments to maintain glycemic control over 
time, and that different treatments can elicit different 
levels of adherence due to side effect profiles, there 
is a requirement to establish the inter-relationships 
between these factors and HbA1c outcomes. Associ-
ations between treatment, outcomes and adherence 
have previously been evaluated4 10 11; however, such 
research has focused on specific classes of therapy or 
restricted populations, without addressing the evolu-
tion of type 2 diabetes and outcomes associated with 
OHA therapy escalation in a general clinical practice 
population. In light of this, the present retrospective 
cohort study aimed to generate evidence, based on a 
large cohort of patients with type 2 diabetes treated 
in UK clinical practice, to quantify inter-relationships 
between OHA treatment choice, line of therapy, medi-
cation adherence, HbA1c, weight and hypoglycemia, 
which may inform clinical management and health 
policy.
ReseaRCH desIgn and meTHOds
study design
This study retrospectively analyzed patients with type 2 
diabetes who were prescribed one of three treatment 
regimens (OHA monotherapy, dual or triple therapy) 
between 1 January 2008 and 31 December 2016. The 
index date was defined as the date of treatment initiation, 
and the baseline data period was defined as the quarter 
prior to the index date. Data were extracted quarterly, 
with measurements based on the last available record 
for each study variable within each period. Patients were 
monitored for up to 365 days post-index date, or until 
death, treatment cessation, treatment intensification to a 
non-examinable regimen, lost to follow-up or the end of 
the study period.
data source
The Clinical Practice Research Datalink (CPRD; 
formerly the General Practice Research Data-
base) contains primary care data for approximately 
11.3 million individuals registered with selected general 
practitioners in the UK.12 In this study, patient-level data 
were extracted from the CPRD to obtain patient demo-
graphic and lifestyle information, as well as informa-
tion on medical diagnoses, symptoms, referrals, hospi-
talizations, deaths and prescriptions, for each patient. 
Prescriptions are generated directly within the system 
and contain the name of the preparation, instructions 
for use, route of administration, dose and number of 
tablets for each entry. Primary care data derived from 
the CPRD have been validated and demonstrated to be 
of high quality13 14 and used in previous observational 
research of diabetes,15–17 including the assessment of 
adherence and HbA1c.4 
Population
Patients eligible for inclusion in this study were aged ≥18 
years at index date with a diagnosis of type 2 diabetes, 
based on a Read code for type 2 diabetes or a prescrip-
tion record of OHA. Patients with gestational or type 1 
diabetes (based on read codes for type 1 diabetes or a 
prescription record indicating first-line insulin therapy), 
diagnosis of polycystic ovary syndrome or malignant 
disease prior to index date and/or during follow-up were 
excluded.
For each treatment cohort, eligible patients were 
required to have at least a 365-day record of prescription 
coverage and a minimum of two prescriptions filled for 
the medication(s) comprising a given regimen. OHA 
monotherapy included all patients prescribed one OHA 
over the study period; OHA dual therapy included 
patients with at least two instances of two simultaneously 
prescribed OHAs with no instances of additional OHA 
prescriptions; OHA triple therapy included patients with 
at least two instances of three simultaneously prescribed 
OHAs with no instances of additional OHA prescrip-
tions. Patients with prior insulin usage or in receipt 
of regimens including GLP-1 were excluded due to 
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inadequate recording of injectable regimens (ie, dose 
and preparation).
By design, patients may have been included in more 
than one cohort at different times during the study 
period, provided they met the eligibility criteria for each 
cohort. Therapy change post-index was defined as cessa-
tion of one or more of the medication(s) comprising 
each regimen and/or initiation of a new treatment.
derived variables
Descriptive analyses were undertaken to compare patient 
profiles, outcomes and patterns of medication adherence 
within and across treatment cohorts. Patient outcomes of 
interest included 1-year HbA1c and weight change from 
baseline (for patients with 365 days of follow-up data), 
1-year hypoglycemic event incidence (total events and 
rate per 1000 patient-years) and medication adherence.
Consistent with methodological approaches advocated 
by the International Society for Pharmacoeconomics and 
Outcomes Research, medication adherence was assessed 
by calculating the medication possession ratio (MPR).18 
In this study, MPR was defined as the total number of 
days of available medication (calculated as the quantity of 
drug prescribed divided by the daily dose), divided by the 
length of the analysis period. For dual and triple OHA 
therapies, overall MPR was calculated as the average MPR 
of all medications comprising each regimen.
If prescription coverage was <365 days for a given 
regimen (due to therapy change or discontinuation) or 
periods between prescriptions were >6 months apart, 
the analysis period was shortened to coincide with the 
expected end date of the last valid prescription. Where 
dose information was absent for prescriptions within 
the analysis period, but present for a minimum of three 
prescriptions, the invalid prescriptions were omitted; and 
the time between the invalid prescription and the next 
valid prescription was subtracted from the denominator 
of the MPR calculation.
Patients with an overall MPR of ≥80% (MPR ≥0.80) 
were considered adherent to treatment; non-adherence 
was defined as MPR <0.80. Consistent with the approach 
of previous studies, patients with MPR calculated as 
>120% were excluded from the analysis.4
statistical analyses
For baseline patient and treatment characteristics, 
descriptive analyses for continuous variables (number of 
patients, mean, SD, median, minimum and maximum 
values) and categorical variables (the number and propor-
tions of patients) were reported. Statistical significance of 
between-group comparisons was estimated using χ2 tests 
(categorical variables) and analysis of variance (contin-
uous variables) to determine significant differences at 
the 5% level of testing.
Multivariate regression analyses were based on a 
general-specific selection methodology, with covariates 
excluded at the 5% level of statistical significance. Overall 
model fit was determined by appropriate goodness-of-fit 
statistics, including the R2 statistic, likelihood ratio test 
and Akaike information criterion and Bayesian informa-
tion criterion. All analyses were undertaken using R soft-
ware for statistical computing.
Linear regression modeling was used to determine the 
association between patient variables, HbA1c and medi-
cation adherence. In patients with 365 days of follow-up 
data, multivariate regression modeling was used to assess 
the influence of observed covariates (demographic, 
clinical and socioeconomic factors, other prescriptions, 
comorbidities and center effects) on MPR and HbA1c 
change over 1 year.
ResulTs
Patient characteristics
A total of 159 799 patients aged ≥18 years within the 
CPRD database were identified as having type 2 diabetes 
between 1 January 2008 and 31 December 2016. After 
inclusion and exclusion criteria were applied, 33 849 
patients were considered eligible for this study. Of these, 
23 925 patients were prescribed OHA monotherapy and 
met the inclusion criteria for this treatment cohort, while 
8406 patients were eligible for inclusion in the OHA dual 
therapy cohort and 1518 patients were included OHA 
triple therapy cohort (online supplementary figure S1).
At baseline, patients included in the OHA mono-
therapy subgroup tended to have lower body weight 
(94.4±21.9 kg; body mass index (BMI) 32.9±6.6 kg/m2), 
a shorter duration of diabetes (0.7±1.3 years), lower base-
line HbA1c (7.8%±1.6%; 62±17.5 mmol/mol) and fewer 
total prescriptions (19.9±18.9). In contrast, the OHA 
triple-therapy cohort had increased body weight at base-
line (98.2±21.8 kg; BMI 33.4±6.6 kg/m2), a longer dura-
tion of diabetes (3.0±1.8 years), higher baseline HbA1c 
(9.1%±1.5%; 76±16.4 mmol/mol), greater total prescrip-
tions (26.9±22.6) and a higher likelihood of receiving 
lipid-lowering and antihypertensive therapies; potentially 
reflective of treatment escalation due to the progres-
sive nature of diabetes and comorbid diseases. Other 
variables including baseline age, proportion of male 
patients, clinical measurements and type 2 diabetes-re-
lated event history were comparable across treatment 
cohorts. Within each OHA cohort, MET, SU and DPP-4i 
were the most commonly prescribed regimens (table 1).
Patient outcomes
Treatment with OHA monotherapy was associated with 
a mean HbA1c reduction of −0.8% (−8.7 mmol/mol) 
over 1 year compared with −0.9% (−9.8 mmol/mol) and 
−1.0% (−10.9 mmol/mol) in patients treated with OHA 
dual and triple therapy, respectively (table 2). Across 
treatments and cohorts, patients who were adherent 
to therapy (MPR ≥0.80) generally experienced signifi-
cantly greater reductions in HbA1c over 1 year (−0.90 to 
−1.14%; −9.8 to −12.5 mmol/mol) than those considered 
non-adherent (−0.49 to −0.69%; −5.4 to −7.5 mmol/mol).
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Table 1 Baseline characteristics of patients with type 2 diabetes in each oral antihyperglycemic agent (OHA) therapy cohort
OHA therapy cohort
OHA monotherapy
(n=23 925)
OHA dual therapy
(n=8406)
OHA triple therapy
(n=1158)
Baseline patient characteristics
  Age (years), mean (SD) 59.2 (12.9) 56.9 (11.9) 56.6 (10.6)
  Male sex, n (%) 14 356 (60.0%) 5475 (65.1%) 1061 (69.9%)
  Current smoker, n (%) 2388 (10.0%) 750 (8.9%) 123 (8.1%)
  Duration of diabetes (years), mean (SD) 0.7 (1.3) 1.9 (1.8) 3.0 (1.8)
  BMI (kg/m2), mean (SD) 32.9 (6.6) 32.8 (6.6) 33.4 (6.6)
  HbA1c (%), mean (SD) 7.8 (1.6) 8.6 (1.6) 9.1 (1.5)
  HbA1c (mmol/mol), mean (SD) 62 (17.5) 70 (17.5) 76 (16.4)
Regimens, n (%)
OHA monotherapy 23 925 (100.0%) – – 
  MET 21 628 (90.4%) – – 
  SU 1758 (7.3%) – – 
  DPP-4i 423 (1.8%) – – 
  Other 116 (0.5%) – – 
OHA dual therapy – 8406 (100.0%) – 
  MET+SU – 4871 (57.9%) – 
  MET+DPP-4i – 2448 (29.1%) – 
  MET+TZD – 466 (5.5%) – 
  MET+SGLT-2i – 232 (2.8%) – 
  SU+DPP-4i – 223 (2.7%) – 
  Other – 166 (2.0%) – 
OHA triple therapy – – 1518 (100.0%)
  MET+SU+DPP-4i – – 985 (64.9%)
  MET+SU+TZD – – 210 (13.8%)
  MET+DPP-4i+SGLT-2i – – 119 (7.8%)
  MET+DPP-4i+TZD – – 104 (6.9%)
  MET+SU+SGLT-2i – – 68 (4.5%)
  Other – – 32 (2.1%)
Prescriptions
  Mean (SD) 19.9 (18.9) 22.8 (19.4) 26.9 (22.6)
  Patients in receipt of lipid-lowering therapy, 
n (%)
17 462 (73.0%) 6512 (77.5%) 1274 (83.9%)
  Patients in receipt of antihypertensive 
therapy, n (%)
14 460 (60.4%) 5037 (59.9%) 973 (64.1%)
Complications at baseline, n (%)
  Microvascular complications* 429 (1.79%) 393 (4.68%) 210 (13.83%)
  Macrovascular complications† 932 (3.90%) 261 (3.10%) 92 (6.06%)
  Other complications‡ 88 (0.37%) 62 (0.74%) 42 (2.77%)
*Microvascular complications include diabetic nephropathy, neuropathy (comprising neuropathy, ulcer and amputation) and retinopathy 
(comprising retinopathy, blindness and macular edema).
†Macrovascular complications include congestive heart failure, ischemic heart disease, myocardial infarction and stroke.
‡Other complications include nausea, gastrointestinal complications, edema, urinary tract infection, acute pancreatitis, fracture, ketoacidosis 
and hypoglycemia.
BMI, body mass index; DPP-4i, dipeptidyl peptidase-4 inhibitor; HbA1c, glycated hemoglobin A1c; MET, metformin; SGLT-2i, sodium-
glucose co-transporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.
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Table 2 One-year change in glycated hemoglobin A1c (HbA1c), weight and hypoglycemia incidence, stratified by oral 
antihyperglycemic agent (OHA) therapy cohort and medication possession ratio (MPR) category
Regimen N
One-year HbA1c change (%), 
mean (95% CI)
One-year HbA1c change 
(mmol/mol), mean (95% CI)
One-year weight change (kg), 
mean (95% CI)
Hypoglycemia
event rate,
n (per 1000 patient-
years)
OHA 
monotherapy
23 925 −0.8 (−0.9 to −0.8)  −8.7 (−9.8 to −8.7) −2.5 (−2.6 to −2.3) 189 (7.9)
  MPR<80% 4401 −0.55 (−0.61 to −0.49) −6.0 (−6.7 to −5.4) −1.64 (−1.94 to −1.34) 29 (6.6)
  MPR≥80% 19 524 −0.90 (−0.93 to −0.87) −9.8 (−10.2 to −9.5) −2.65 (−2.80 to −2.50) 160 (8.2)
  Difference* −0.35 (−0.41 to −0.28); p<0.001 −3.8 (−4.5 to −3.1); p<0.001 −1.01 (−1.34 to −0.67); p<0.001 131 (RR 1.24; p=0.303)
OHA dual 
therapy
8406 −0.9 (−1.0 to −0.9) −9.8 (−10.9 to −9.8) 0.6 (0.4 to 0.8) 152 (18.1)
  MPR<80% 1610 −0.69 (−0.79 to −0.58) −7.5 (−8.6 to −6.3) 0.31 (−0.22 to 0.83) 27 (16.8)
  MPR≥80% 6796 −0.97 (−1.02 to −0.92) −10.6 (−11.1 to −10.1) 0.67 (0.46 to 0.88) 125 (18.4)
  Difference* −0.28 (−0.40 to −0.17); p<0.001 −3.1 (−4.4 to −1.9); p<0.001 0.36 (−0.20 to 0.93); p=0.210 98 (RR 1.10; p=0.757)
OHA triple 
therapy
1518 −1.0 (−1.1 to −0.9) −10.9 (−12.0 to −9.8) 0.5 (0.0 to 0.9) 58 (38.2)
  MPR<80% 291 −0.49 (−0.74 to −0.25) −5.4 (−8.1 to −2.7) 0.26 (−0.65 to 1.17) 6 (20.6)
  MPR≥80% 1227 −1.14 (−1.25 to −1.04) −12.5 (−13.7 to −11.4) 0.50 (0.03 to 0.97) 52 (42.4)
  Difference* −0.65 (−0.92 to −0.38); p<0.001 −7.1 (−10.1 to −4.2);  p<0.001 0.24 (0.79 to 1.27);  p=0.642 46 (RR 2.06;  p=0.096)
*Difference relates to MPR ≥80% versus MPR <80%.
RR, rate ratio.
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On average, OHA monotherapy was associated with 
weight loss over 1 year (−2.5 kg); within this cohort, weight 
reductions were greater among adherent (−2.65 kg) 
compared with non-adherent (−1.64 kg) patients. In the 
dual and triple OHA cohorts, weight tended to increase, 
more so for adherent (+0.50 to +0.67 kg) compared with 
non-adherent (+0.26 to +0.31 kg) patients; however, this 
overall result included a trend of weight gain for SU and 
TZD-based regimens, and weight loss for DPP-4i and 
SGLT-2i-based regimens (table 2; online supplementary 
Table S1).
Despite having higher baseline HbA1c, the incidence 
of recorded hypoglycemia events (per 1000 patient-
years) was greatest in the OHA triple-therapy cohort 
(38.2), compared with patients receiving OHA mono-
therapy and dual-therapy regimens (7.9 and 18.1, respec-
tively). Within the OHA monotherapy cohort, treatment 
with SU was associated with a higher hypoglycemia event 
rate (15.4) versus MET and DPP-4i therapies (7.3 and 
9.5, respectively). Similarly, the incidence of hypogly-
cemia was generally higher among patients who received 
dual-therapy and triple-therapy regimens containing 
SU, compared with those containing DPP-4i, TZD and/
or SGLT-2i agents (online supplementary Table S1). 
Observed event rates were higher among adherent versus 
non-adherent patients in the OHA monotherapy (8.2 vs 
6.6), dual-therapy (18.4 vs 16.8) and triple-therapy (42.4 
vs 20.6) cohorts, reflecting an increase in hypoglycemia 
incidence among adherent patients across therapy lines 
(table 2).
levels of adherence and glycemic control
Medication adherence was highest in the OHA mono-
therapy cohort (81.6%), followed by dual-therapy (80.8%) 
and triple-therapy (80.8%) cohorts (online supplemen-
tary Table S1). Adherence by regimen (MPR ≥0.80; 
95% CI) for OHA monotherapy was highest for DPP-4i 
agents (89.8%; 87.0% to 92.7%). For the two most 
commonly observed dual OHA therapies, MET+DPP-4i 
(29% of patients) was associated with a higher level of 
adherence (83.3%; 81.8% to 84.8%), compared with 
MET+SU (58% of patients) that had the lowest adher-
ence (79.6%; 78.5% to 80.7%). In patients treated with 
triple OHA therapies, medication adherence across regi-
mens was similar.
As shown in figure 1, increasing levels of medication 
adherence were typically associated with greater 1-year 
HbA1c reductions across all lines of OHA therapy. In 
absolute terms, the OHA triple-therapy cohort had the 
greatest level of HbA1c change (−0.17 to −1.20%; −1.9 to 
−13.1 mmol/mol), followed by the dual (−0.60 to −1.04%; 
−6.6 to −11.4 mmol/mol) and monotherapy (−0.49 to 
−0.94%; −5.4 to −10.3 mmol/mol) cohorts.
Predictors of adherence and glycemic control
Factors predictive of MPR were evaluated for each 
OHA cohort in linear regression analyses. Across OHA 
cohorts, patient age, baseline HbA1c, change in BMI 
and/or change in total cholesterol were significant varia-
bles related to MPR variability (table 3). Consistent with 
observations of patient outcomes, coefficient estimates 
for change in BMI were negative in the OHA mono-
therapy cohort, and positive in patients receiving OHA 
dual therapy. Using a regression model that predicted 
1-year change in HbA1c as a function of MPR, it was esti-
mated that a 10% improvement in MPR, when all other 
variables were held constant, was associated with a −0.09% 
(−1.0 mmol/mol), −0.09% (−1.0 mmol/mol) and −0.21% 
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Figure 1 One-year change in glycated hemoglobin A1c (HbA1c), stratified by medication possession ratio category and oral 
antihyperglycemic agent therapy cohort.
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(−2.3 mmol/mol) change in HbA1c for OHA mono, dual 
and triple therapy, respectively.
COnClusIOns
Using real-world data from 33 849 patients with type 
2 diabetes in UK clinical practice, this study sought to 
evaluate the evolution of type 2 diabetes and outcomes 
associated with OHA therapy escalation as a function 
of medication adherence. Analyses found that reduced 
medication adherence was associated with smaller 
HbA1c reductions among patients treated with OHA 
monotherapy, dual-therapy and triple-therapy regimens. 
One-year reductions in HbA1c were greater among 
adherent (−0.90 to −1.14%; −9.8 to −12.5 mmol/mol) 
compared with non-adherent patients (−0.49 to −0.69%; 
−5.4 to −7.5 mmol/mol) and a 10% improvement in MPR 
was associated with a −0.09% (−1.0 mmol/mol), −0.09% 
(−1.0 mmol/mol) and −0.21% (−2.3 mmol/mol) change 
in HbA1c for OHA monotherapy, dual therapy and 
triple therapy, respectively. Collectively, these findings 
support the notion that modest increases in medication 
adherence can bring about meaningful improvements 
in HbA1c control as the requirement to escalate therapy 
increases.
On average, hypoglycemia was more frequent among 
adherent patients compared with non-adherent patients, 
with rate ratios of 1.24, 1.10 and 2.06 associated with 
OHA monotherapy, dual therapy and triple therapy, 
respectively. Within each OHA cohort, adherent patients 
tended to lose more weight (OHA monotherapy) or gain 
more weight (OHA dual and triple therapy) compared 
with non-adherent patients. These findings are consistent 
with a regimen–outcome interaction that may be medi-
ated via medication adherence. For instance, across the 
OHA treatment paradigm, regimens typically associated 
with weight loss and lower incidence of hypoglycemia 
were generally associated with better medication adher-
ence and improved glycemic control.
The health economic value of type 2 diabetes medi-
cation is driven by its expected therapeutic profile, in 
addition to patient and clinician treatment preferences. 
Key barriers to achieving good medication adherence 
include treatment-related hypoglycemia and weight 
gain3; in this context, guidelines suggest that DPP-4i 
or SGLT-2i therapies are associated with weight loss 
or neutrality and low risk of hypoglycemia, while TZD 
regimens cause weight gain and SU-based therapies are 
associated with both weight gain and moderate hypogly-
cemia risk.19 Data arising from this study coincide with 
such guidance and extend this notion to demonstrate 
that patients treated with OHA regimens associated with 
weight loss and lower hypoglycemia frequency tended 
to achieve better adherence and HbA1c control. Impor-
tantly, this was observed across all lines of OHA therapy, 
suggesting that adherence may be an increasingly 
important determinant of glycemic control as patients 
escalate from OHA monotherapy to dual-therapy and 
triple-therapy regimens.
To our knowledge, this is the first study to evaluate a 
large general cohort of UK patients with type 2 diabetes 
in order to assess the associations between adherence and 
clinical outcomes across the OHA treatment paradigm. 
This research builds on existing studies that demonstrate 
associations between adherence and HbA1c control,4 
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Table 3 Multiple linear regression model predicting 1-year glycated hemoglobin A1c (HbA1c) change as a function of 
medication possession ratio (MPR), stratified by oral antihyperglycemic agent (OHA) therapy cohort
Multivariate model
Value SE t-value p-value
OHA monotherapy 
Change in HbA1c (%)
  MPR (%) −0.892 0.076 −11.680 0.000
  Constant −0.002 0.073 −0.030 0.974
MPR (%)
  Age (years) 0.002 0.000 10.110 0.000
  Change in BMI (kg/m2) −0.003 0.001 −2.760 0.006
  Baseline HbA1c (%) −0.002 0.002 −1.400 0.162
  Change in total cholesterol −0.016 0.002 −7.270 0.000
  Constant 0.827 0.019 42.780 0.000
OHA dual therapy
Change in HbA1c (%)
  MPR (%) −0.859 0.155 −5.550 0.000
  Constant −0.133 0.143 −0.930 0.353
MPR (%)
  Age (years) 0.002 0.000 6.320 0.000
  Change in BMI (kg/m2) 0.004 0.001 2.420 0.015
  Baseline HbA1c (%) −0.007 0.002 −3.400 0.001
  Change in total cholesterol −0.012 0.003 −4.230 0.000
  Constant 0.874 0.023 37.300 0.000
OHA triple therapy
Change in HbA1c (%)
  MPR (%) −2.058 0.348 −5.920 0.000
  Constant 0.840 0.319 2.630 0.009
MPR (%)
  Age (years) 0.001 0.001 2.170 0.031
  Change in BMI (kg/m2) −0.001 0.004 −0.220 0.823
  Baseline HbA1c (%) −0.013 0.005 −2.610 0.009
  Change in total cholesterol −0.016 0.008 −1.930 0.054
  Constant 0.941 0.063 15.050 0.000
BMI, body mass index.
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and hypoglycemia and cardiovascular risk,20 in specific 
patient populations or for individual treatments.
There are several important limitations associated 
with this research. Observational studies that stratify 
outcomes by therapy type are potentially subject to the 
bias of ‘confounding by indication’, where observed 
patterns within the data are a function of the patient 
phenotype, which may in turn dictate the prescription of 
a specific therapy. Potential confounding factors may not 
be captured within the CPRD database (such as educa-
tional and professional status); thus, predicting causality 
between treatment and outcome should be interpreted 
with these limitations in mind. To further minimize 
the impact of confounding in this study, homogenous 
OHA cohorts were selected for analysis; and stratifica-
tion and statistical adjustment were used as the principal 
methods of accounting for differences in patient type 
and prescribing choice on study outcomes.
An additional limitation of CPRD-derived data relates 
to the under-reporting of hypoglycemia, as patients may 
often self-manage an event and not present to a physi-
cian. While there are no data to confirm this, we conse-
quently expect that fewer hypoglycemic events were 
captured by the CPRD and that such events were more 
likely to be severe. As a result, data describing hypogly-
cemia incidence, and its influence on medication adher-
ence and clinical outcomes, may be underestimated in 
this retrospective study. The under-reporting of hypo-
glycemia may have additionally led to spurious compari-
sons between OHA regimens; for example, the relatively 
high hypoglycemia event rate observed in patients 
treated with MET monotherapy compared with SU 
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(7.3 vs 15.4 events per 1000 patient-years, respectively) 
may be attributed to the comparatively low number of 
patients (21 628 vs 1758) and recorded events (158 vs 
27) in the SU monotherapy cohort. Moreover, although 
the high incidence of hypoglycemia observed in the 
OHA triple-therapy cohort may reflect greater HbA1c 
reductions and/or treatment regimens associated with 
higher hypoglycemia risk, patient numbers are compar-
atively low in this cohort, and associated data should 
thus be interpreted with caution. Finally, we were unable 
to adequately assess medication adherence in patients 
treated with injectable agents, including GLP-1 receptor 
agonist and insulin-based therapies, due to a paucity 
of CPRD data characterizing factors including doses, 
preparations or the full range of potential treatment-re-
lated side effects. Examining the impact of OHA dosing 
frequency on medication adherence and treatment 
outcomes was beyond the design and objectives of the 
present study; however, as dosing frequency may repre-
sent an important determinant of patient adherence 
and subsequent outcomes, this relationship is indicated 
as an area for future research.
In conclusion, improving HbA1c is the cornerstone 
of type 2 diabetes therapy, which serves to manage 
glycemic control and reduce the risks of diabetes-re-
lated complications, morbidity and mortality. Improve-
ments in HbA1c are determined by treatment choice 
and medication adherence; factors which are inter-
related and further confounded by patient type and 
place in the OHA treatment paradigm. This retrospec-
tive study of routinely collected UK primary care data 
sought to evaluate associations between medication 
adherence and clinical outcomes among patients with 
type 2 diabetes treated with OHA regimens. Across all 
lines of OHA therapy examined, lower MPR was asso-
ciated with smaller HbA1c reductions, suggesting that 
increased medication adherence can bring about mean-
ingful improvements in HbA1c control as the require-
ment to escalate therapy increases. Across the OHA 
treatment paradigm, regimens associated with weight 
loss and the avoidance of hypoglycemia were gener-
ally associated with better medication adherence and 
improved glycemic control.
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